Med Business World

Your source for healthcare business

Karin Eriksen

Justrite® Develops Groundbreaking Solution for the Growing Dangers of Lithium-Ion Battery Fires

In response to the critical need for safe storage and charging of lithium-ion batteries, Justrite announces the launch of its state-of-the-art Lithium-Ion Battery Charging Cabinet. Featuring the innovative 9-Layer ChargeGuard™ Containment System, this cutting-edge cabinet is engineered to prevent catastrophic losses…

BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000

On May 10, 2024, the BGI-Heilongjiang Omics Health Axis Intelligent Laboratory (BGI-HL OHA Intelligent Laboratory) was inaugurated in Harbin, Heilongjiang province, China, marking a significant advance in the province’s efforts to address public health challenges. Utilizing the ‘13311i GigaLab’ technological framework, this facility supports vital life…

High Potent Containment Provider ONFAB Enters USA Market

ONFAB, a leading European provider of single-use, flexible containment solutions for the pharmaceutical industry, has officially launched business operations in the United States in conjunction with parent company Savillex. The company’s American hub will be located within the Savillex headquarters in Eden Prairie,…

Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects

The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 million Americans a year developing this condition. Treating AKs before…

Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure

CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective,…

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for…

Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA

Arctic Therapeutics ehf, an Icelandic drug development company and partner Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced approval by the European Medicines Agency (EMA) for…

New Vision-Training Software Improves Low Vision

Marking the Low Vision awareness month of February, RevitalVision announced the expansion of their team in India as part of their commitment to make their US FDA-cleared vision-training software program available to maximum eye specialists in India to support their…

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today presented initial results from Phase 1 of its ongoing evaluation of HMB-001. A novel bispecific antibody, HMB-001 is in development as a prophylactic…

Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy

 Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, is pleased to announce the Health Canada approval of MYALEPTA™ (metreleptin for injection). As an adjunct…